Q2 EPS Estimate for Avadel Pharmaceuticals Cut by Analyst

Avadel Pharmaceuticals plc (NASDAQ:AVDL - Free Report) - Research analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Avadel Pharmaceuticals in a research report issued on Tuesday, March 4th. HC Wainwright analyst O. Livnat now expects that the company will post earnings per share of ($0.06) for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a "Buy" rating and a $21.00 target price on the stock. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Avadel Pharmaceuticals' FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $1.44 EPS, FY2028 earnings at $1.54 EPS and FY2029 earnings at $1.83 EPS.

Several other equities research analysts have also recently weighed in on the stock. Piper Sandler reduced their target price on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. UBS Group reduced their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, January 13th. Needham & Company LLC restated a "buy" rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research report on Monday, March 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "buy" rating and a $12.00 target price for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Avadel Pharmaceuticals currently has an average rating of "Buy" and an average price target of $19.88.

Remove Ads

Avadel Pharmaceuticals Stock Up 5.1 %

NASDAQ AVDL traded up $0.39 during midday trading on Friday, hitting $8.00. The company had a trading volume of 1,418,449 shares, compared to its average volume of 1,186,317. The firm has a fifty day simple moving average of $8.51 and a two-hundred day simple moving average of $11.24. Avadel Pharmaceuticals has a fifty-two week low of $7.39 and a fifty-two week high of $19.09. The stock has a market cap of $770.90 million, a price-to-earnings ratio of -10.13 and a beta of 1.57.

Insiders Place Their Bets

In other news, CFO Thomas S. Mchugh purchased 5,000 shares of Avadel Pharmaceuticals stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of $10.49 per share, for a total transaction of $52,450.00. Following the completion of the transaction, the chief financial officer now directly owns 85,500 shares in the company, valued at approximately $896,895. This represents a 6.21 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter J. Thornton acquired 10,000 shares of the firm's stock in a transaction on Monday, January 13th. The shares were purchased at an average cost of $8.04 per share, for a total transaction of $80,400.00. Following the completion of the purchase, the director now directly owns 104,055 shares of the company's stock, valued at approximately $836,602.20. The trade was a 10.63 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased 22,300 shares of company stock worth $196,512 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AVDL. Janus Henderson Group PLC increased its holdings in Avadel Pharmaceuticals by 5.7% during the 4th quarter. Janus Henderson Group PLC now owns 14,080,219 shares of the company's stock valued at $148,117,000 after purchasing an additional 753,332 shares in the last quarter. Two Seas Capital LP grew its holdings in shares of Avadel Pharmaceuticals by 90.6% during the fourth quarter. Two Seas Capital LP now owns 4,296,449 shares of the company's stock worth $45,156,000 after purchasing an additional 2,042,669 shares during the last quarter. Braidwell LP increased its stake in shares of Avadel Pharmaceuticals by 21.2% in the fourth quarter. Braidwell LP now owns 4,105,726 shares of the company's stock valued at $43,151,000 after buying an additional 716,787 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Avadel Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 3,953,247 shares of the company's stock valued at $41,549,000 after buying an additional 90,147 shares during the last quarter. Finally, Wealth Effects LLC lifted its position in Avadel Pharmaceuticals by 4.9% during the 4th quarter. Wealth Effects LLC now owns 2,344,130 shares of the company's stock worth $24,637,000 after buying an additional 110,359 shares in the last quarter. 69.19% of the stock is owned by institutional investors and hedge funds.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.